Real-World Evidence on Weight Loss and Safety With Semaglutide in Obesity Telehealth: A Large Retrospective Cohort Study.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Real-World Evidence on Weight Loss and Safety With Semaglutide in Obesity Telehealth: A Large Retrospective Cohort Study.
- Published In:
- Obesity (Silver Spring, Md.), 34(3), 729-737 (2026)
- Authors:
- Tchang, Beverly, Broffman, Lauren, Manalac, Raoul, Chai, Sam, Samonas, Nicholas, Barnes, Melynda, Allison, David B
- Database ID:
- RPEP-16232
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-16232APA
Tchang, Beverly; Broffman, Lauren; Manalac, Raoul; Chai, Sam; Samonas, Nicholas; Barnes, Melynda; Allison, David B. (2026). Real-World Evidence on Weight Loss and Safety With Semaglutide in Obesity Telehealth: A Large Retrospective Cohort Study.. Obesity (Silver Spring, Md.), 34(3), 729-737. https://doi.org/10.1002/oby.70120
MLA
Tchang, Beverly, et al. "Real-World Evidence on Weight Loss and Safety With Semaglutide in Obesity Telehealth: A Large Retrospective Cohort Study.." Obesity (Silver Spring, 2026. https://doi.org/10.1002/oby.70120
RethinkPeptides
RethinkPeptides Research Database. "Real-World Evidence on Weight Loss and Safety With Semagluti..." RPEP-16232. Retrieved from https://rethinkpeptides.com/research/tchang-2026-realworld-evidence-on-weight
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.